Literature DB >> 18069042

Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4.

Ying Wang1, Yingmei Zhang, Wenling Han, Dan Li, Linjie Tian, Caihua Yin, Dalong Ma.   

Abstract

Human chemokine-like factor 1 (CKLF1) exhibits chemotactic effects on leukocytes. A previous study demonstrated that CKLF1 is a functional ligand for human CC chemokine receptor 4 (CCR4). In this study, N-terminal amino acid sequencing of secreted CKLF1 protein showed that it contains at least two peptides, C27 and C19. To examine whether C27 or C19 play a role via CCR4, C27 and C19 were chemically synthesized and analyzed by chemotaxis, calcium mobilization, and receptor internalization assays in CCR4-tranfected HEK293 cells or Hut78 cells. The chemotaxis assay showed that C27 could induce chemotaxis to CCR4-transfected HEK293 cells or Hut78 cells while C19 had weaker chemotactic activity, especially in Hut78 cells. C27- or C19-induced chemotaxis was abolished by pertussis toxin, suggesting the involvement of a Gi/o pathway. C27- or C19-induced chemotaxis was also inhibited by an antagonist of CCR4 that show good binding potency, excellent chemotaxis inhibitory activity and selectivity toward CCR4, suggesting that their chemotactic activity specifically involved CCR4. The chemotactic response of CCR4-tranfected HEK293 cells to C27 or C19 was markedly inhibited by preincubation with TARC/CCL17. TARC/CCL17 effectively desensitized the calcium mobilization induced by C27 or C19. Similarly, both of C27 or C19 also desensitized the calcium mobilization and chemotaxis of CCR4-tranfected HEK293 cells in response to TARC/CCL17, suggesting that they might interact with a common receptor. Both C27- and C19-induced clear internalization of CCR4-EGFP. These results confirm that the secreted peptides of CKLF1, C27 and C19, have functional activation via CCR4.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069042     DOI: 10.1016/j.biocel.2007.10.028

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  9 in total

1.  Chemokine-like factor 1: A promising therapeutic target in human diseases.

Authors:  Xiaopeng Cai; Jingwen Deng; Qianqian Ming; Huiqiang Cai; Zhi Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-26

Review 2.  Research progress in cytokines with chemokine-like function.

Authors:  Kai Zhang; Shuang Shi; Wenling Han
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

3.  Antagonistic effect of C19 on migration of vascular smooth muscle cells and intimal hyperplasia induced by chemokine-like factor 1.

Authors:  Tao Zhang; Zhengguo Qiao; Feng Chen; Xiaoming Zhang; Jiang Xiong; Xin Jia; Jian Chen; Chenyang Shen; Wei Guo
Journal:  Mol Biol Rep       Date:  2012-12-01       Impact factor: 2.316

Review 4.  Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: Latest Advances.

Authors:  Mengxia Li; Fangzhou Luo; Xinyao Tian; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

5.  Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis.

Authors:  Yaqi Tan; Yixuan Wang; Li Li; Jinyu Xia; Shiguang Peng; Yanling He
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

6.  Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats.

Authors:  Ling Lei Kong; Zhi Yuan Wang; Ning Han; Xiao Mei Zhuang; Zhen Zhen Wang; Hua Li; Nai Hong Chen
Journal:  J Neuroinflammation       Date:  2014-06-20       Impact factor: 8.322

7.  C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis.

Authors:  Yi Zheng; Yixuan Wang; Xuan Zhang; Yaqi Tan; Shiguang Peng; Le Chen; Yanling He
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

8.  A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma.

Authors:  Yang Zhang; Yinfang Wu; Hui Qi; Junhai Xiao; Hongwei Gong; Yan Zhang; Enquan Xu; Song Li; Dalong Ma; Ying Wang; Wen Li; Huahao Shen
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

9.  Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Authors:  Hongwei Gong; Hui Qi; Wei Sun; Yang Zhang; Dan Jiang; Junhai Xiao; Xiaohong Yang; Ying Wang; Song Li
Journal:  Molecules       Date:  2012-08-20       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.